A new analysis of dozens of animal studies evaluating the effects of the cholesterol-lowering statin class of drugs on atherosclerosis found larger positive effects in studies not sponsored by the pharmaceutical industry as compared to those that were industry sponsored.
An updated and expanded review of clinical research papers on drugs and medical devices finds that industry-sponsored studies are more likely to lead to favorable results, including reports of greater benefits and fewer harmful side effects.
Health policy expert Lisa Bero, PhD, is hailed in the latest issue of The Lancet for tackling hot-button subjects such as financial biases in drug research.
Published results of drug trials sponsored by the pharmaceutical industry are more likely than trials not sponsored by the industry to favor drug over placebo, according to
The same level of legal scrutiny that applies to research funded by the US government should apply to research funded by industry, according to UCSF School of Pharmacy faculty member Lisa Bero, PhD, and co-authors of a study that appeared July
